Last reviewed · How we verify
Moderate to severe atopic dermatitis in children 12 years of age and older
Approved treatments
- Abrocitinib Suspension F1 · Pfizer
- Abrocitinib Suspension F6 · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe atopic dermatitis in children 12 years of age and older patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe atopic dermatitis in children 12 years of age and older treatment landscape brief
- Moderate to severe atopic dermatitis in children 12 years of age and older treatment updates RSS
Frequently asked questions about Moderate to severe atopic dermatitis in children 12 years of age and older
What drugs treat Moderate to severe atopic dermatitis in children 12 years of age and older?
Tracked treatments include Abrocitinib Suspension F1, Abrocitinib Suspension F6.
What is the treatment for Moderate to severe atopic dermatitis in children 12 years of age and older?
Standard treatment for Moderate to severe atopic dermatitis in children 12 years of age and older includes Abrocitinib Suspension F1, Abrocitinib Suspension F6. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe atopic dermatitis in children 12 years of age and older patent cliff · Moderate to severe atopic dermatitis in children 12 years of age and older CI report
- Treatment: Abrocitinib Suspension F1 · Pfizer
- Treatment: Abrocitinib Suspension F6 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing